Team:NTU-Singapore/Project

From 2008.igem.org

(Difference between revisions)
m
(→Introduction)
Line 8: Line 8:
<div id="maincontent" style="width:900px;float:left;margin-top:-30px;margin-left:10px;padding:5px;border-style:inset;">
<div id="maincontent" style="width:900px;float:left;margin-top:-30px;margin-left:10px;padding:5px;border-style:inset;">
=Introduction=
=Introduction=
-
The focus of the NTU iGEM team’s project is the use of bacteriocins as antimicrobials. This objective will be achieved by re-engineering the genome of a non-pathogenic Escherichia coli, (E.coli) strain, making it capable of colicin E7 production. The E. Coli would then function as a carrier for colicin E7 which would then induce cell death in a pathogenic strain of E. coli, O157:H7.<br>
+
<html><b><center>ENGINEERING COLICIN E7 PRODUCTION SYSTEM TO KILL ENTEROHEMORRHAGIC ESCHERICHIA COLI O157:H7 (EHEC) VIA THE DETECTION OF EHEC SYMPTOMS </b></center><br><br>
-
E. coli O157:H7 is an enterohemorrhagic strain, i.e. it causes hemorrhagic colitis (bloody diarrhea). In some cases, infection by O157:H7 leads to acute renal failure. Current treatments of the infection, known commonly as EHEC, include blood transfusion and dialysis, as O157:H7 is resistant to existing antibiotics available in the market.<br>
+
 
-
Besides functioning as a carrier of colicin E7, our proposed system is able to detect symptoms of EHEC, specifically, internal hemorrhaging and presence of the bacteria. Upon detection of the two forementioned, the system would trigger the synthesis of a lysis gene, which would release the colicin E7, allowing it to attack the pathogenic strain O157:H7.  
+
 
-
</div>
+
The focus of the NTU @ iGEM Team's project is the use of bacteriocins (i.e. colicin E7) for the killing of the Escherichia Coli O157:H7 enterohemorrhagic strain (EHEC), which causes symptoms such as bloody diarrhea. Currently, there are no antibiotics that can cure EHEC. This is a prevalent medical problem that has a reach of a wide population. The team intends to achieve its objective by engineering a biological system that <br>
-
<!---End of main content--->
+
i) produces Colicin E7,<br>  
-
</div>
+
ii) detects the symptoms (e.g. blood) and presence of pathogenic E-Coli, and <br>
-
<!---End of body--->
+
iii) releases E7 through lysis. <br>
 +
<br>
 +
The system will be developed using  the following proposed protocol: Colicin E7 production is achieved by the insertion of the colicin E7 gene and colicin immunity gene downstream of and under regulation of the LacI gene, found in wild type E. Coli K12 strain. The production of the lysis protein functions under the control of an AND gate, constructed by two plasmids, and whose inputs are presence of Fe2+ ions  (attributed to presence of blood) and Ai2 (attributed to presence of O157:H7). <br><br>LuxS knock-out was carried out to eliminate Ai2 production of K12, obtaining mutant W3110 strain, thus ensuring that Ai2 detected is purely from O157:H7. Upon detection of Fe2+ ions, T7ptag expression is initiated producing T7 RNA Polymerase. Upon detection of phosphorylated Ai2, expression of the SupD gene is initiated by activation of promoter LsrA, producing amber suppressor tRNA. In combination, the two upstream inputs activate the expression of the lysis protein gene, under the influence of R6K origin, resulting in amplified response of the AND gate. <br><br>The team also intends to characterize the various parts and devices used in the project, in terms of sensitivity to temperature and input concentrations by fluorescence assay and Western blotting. The team will also present the modeling of the final system.
 +
</html>

Revision as of 07:50, 3 July 2008


Introduction

ENGINEERING COLICIN E7 PRODUCTION SYSTEM TO KILL ENTEROHEMORRHAGIC ESCHERICHIA COLI O157:H7 (EHEC) VIA THE DETECTION OF EHEC SYMPTOMS


The focus of the NTU @ iGEM Team's project is the use of bacteriocins (i.e. colicin E7) for the killing of the Escherichia Coli O157:H7 enterohemorrhagic strain (EHEC), which causes symptoms such as bloody diarrhea. Currently, there are no antibiotics that can cure EHEC. This is a prevalent medical problem that has a reach of a wide population. The team intends to achieve its objective by engineering a biological system that
i) produces Colicin E7,
ii) detects the symptoms (e.g. blood) and presence of pathogenic E-Coli, and
iii) releases E7 through lysis.

The system will be developed using the following proposed protocol: Colicin E7 production is achieved by the insertion of the colicin E7 gene and colicin immunity gene downstream of and under regulation of the LacI gene, found in wild type E. Coli K12 strain. The production of the lysis protein functions under the control of an AND gate, constructed by two plasmids, and whose inputs are presence of Fe2+ ions (attributed to presence of blood) and Ai2 (attributed to presence of O157:H7).

LuxS knock-out was carried out to eliminate Ai2 production of K12, obtaining mutant W3110 strain, thus ensuring that Ai2 detected is purely from O157:H7. Upon detection of Fe2+ ions, T7ptag expression is initiated producing T7 RNA Polymerase. Upon detection of phosphorylated Ai2, expression of the SupD gene is initiated by activation of promoter LsrA, producing amber suppressor tRNA. In combination, the two upstream inputs activate the expression of the lysis protein gene, under the influence of R6K origin, resulting in amplified response of the AND gate.

The team also intends to characterize the various parts and devices used in the project, in terms of sensitivity to temperature and input concentrations by fluorescence assay and Western blotting. The team will also present the modeling of the final system.
Retrieved from "http://2008.igem.org/Team:NTU-Singapore/Project"